Zogenix (ZGNX) Receives a Buy from Mizuho Securities

By Austin Angelo

Mizuho Securities analyst Difei Yang maintained a Buy rating on Zogenix (ZGNXResearch Report) today and set a price target of $65.00. The company’s shares closed last Monday at $46.83.

According to TipRanks.com, Yang ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -2.8% and a 38.6% success rate. Yang covers the Healthcare sector, focusing on stocks such as Audentes Therapeutics, Xeris Pharmaceuticals, and Revance Therapeutics.

Zogenix has an analyst consensus of Strong Buy, with a price target consensus of $63.71, implying a 35.6% upside from current levels. In a report issued on November 25, Northland Securities also assigned a Buy rating to the stock with a $60.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $56.50 and a one-year low of $33.43. Currently, Zogenix has an average volume of 403.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.